Rtw Biotech Regulatory News (RTW)

LEI: 549300Q7EXQQH6KF7Z84

08 December 2020

RTW Venture Fund Limited

New Investment in Nuance Pharma

RTW Co-Leads $181 Million Financing Round in Nuance Pharma

RTW Venture Fund Limited (the "Company"), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement by Nuance Pharma ("Nuance") on 08 December 2020 of its completion of a $181 million Series D financing round co-led by RTW Investments, LP (the "Investment Manager").

The Company, alongside other investment vehicles of the Investment Manager, confirms that it participated in the financing round together with other investment firms.

Nuance is a China-based privately held fully integrated pharmaceutical company engaged in creating value through China's specialty pharmaceutical markets, with an established focus on iron deficiency, pain management and respiratory conditions. Nuance plans to use the proceeds from the financing round to advance ongoing research and development of Nuance's existing products and business development of potential new assets.

The Company's investment in Nuance is its eleventh portfolio company addition in 2020, bringing the total number of companies in its core portfolio to eighteen. The Investment Manager is looking forward to growing the Company's investment pipeline and updating shareholders on further opportunities in due course.

Roderick Wong, MD, Managing Partner and Chief Investment Officer of the Investment Manager, said:

"We are excited to co-lead this financing round and support Nuance's effort to bring important medicines for iron deficiency, pain management and respiratory conditions to Chinese patients. Investing globally is a strategic priority for the Company and we are pleased to be a part of advancing promising innovative medical products in China."

Full text of the Nuance's announcement is contained below.

For Further Information

RTW Investments, LP +1 (646) 343 9280Stephanie Sirota, Chief Business OfficerAlexandra Taracanova, PhD, Director of Investor Relations

Julia Enright, Business Development Associate

Buchanan +44 (0)20 7466 5107Charles Ryland

Henry Wilson

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading healthcare investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.

Nuance Pharma Closes Series D Financing

Funds will support ongoing research & development and further business development

SHANGHAI, China, December 08, 2020 (PR Newswire) - Nuance Pharma, a biopharmaceutical company engaged in creating value through China's specialty pharmaceutical markets with an established focus on iron deficiency, pain management and respiratory, today announced that it has successfully closed its Series D financing which amounted to US$181 million of funding.

The Series D financing is led by RTW Investments, LP, and GT Fund with additional support from existing investors including CBC Group, Matrix Partners China and HBM Healthcare Investments, and new investors including Konruns Pharmaceutical (603590.SH), etc.

Proceeds from the financing will be used in the ongoing research and development of Nuance's existing products and business development of potential new assets. To date, the Company has made important progress with its broad pipeline and seeks to further strengthen its presence in these key therapeutic areas.

"This is an important milestone for Nuance Pharma, which reinforces our deep industry expertise and strategic business model." said Mark Lotter, founder and CEO of Nuance. "We are well-positioned to advance the clinical development of our robust therapeutics pipeline, and we look forward to bringing in more assets to China and building a leading presence in these key therapeutic areas".

About Nuance

Nuance is a fully integrated pharmaceutical company engaged in creating value through China's specialty pharmaceutical markets, with an established focus on iron deficiency, pain management and respiratory. Nuance is founded in 2014 and has received multiple rounds of financing from leading investors which include the CBC Group (formerly C-Bridge Capital), one of the largest and most active healthcare-dedicated investment firms in Asia, and Matrix Partners China.

About CBC Group

CBC Group (formerly C-Bridge Capital) is one of the largest and most active healthcare-dedicated investment firms in Asia focused on platform-building and buyout opportunities across three core areas within the healthcare sector: pharmaceutical & biotech, medtech and healthcare services. CBC's operationally intensive approach empowers healthcare sector champions to make transformative changes to enable sustainable long-term growth, fulfill unmet medical needs and continuously improve the standard of living and quality of care in China and the rest of Asia. Founded in 2014, CBC has a strong team of investment, healthcare and portfolio management professionals based across Singapore, Shanghai, Beijing, Hong Kong and New York.

About RTW Investments, LP

RTW Investments, LP ("RTW") is a New York-based, global, full life-cycle investment firm that focuses on identifying transformational and disruptive innovations in biopharmaceutical and medical technologies. As a leading partner of industry and academia, RTW combines deep scientific expertise with a solution-oriented investment approach to support emerging medical therapies and the companies and/or academics developing them.

About GT Fund

Zhejiang Manufacturing Fund LLP as part of Guoxin Guotong Fund LLP (collectively "GT Fund") is a private equity fund incorporated in Hangzhou, China, in 2017 with total size of CNY 10 billion (c.US$1.4 billion). It has the mandate to provide capital and professional support to industrial partners in the region. GT Fund specializes in cross-border investment projects following the principles of market-orientation, professionalism and internationalization and is actively investing in the field of healthcare, advanced manufacturing, clean energy, etc. GT Fund's portfolio of investments seeks to provide superior risk-adjusted returns to its co-investors as well as limited partners. Guoxin Guotong Fund LLP is a private equity fund established in 2016 with total size of CNY 150 billion (c.US$21.1 billion).